Neurofibromin 2 (NF2) (NF2)

Neurofibromin 2 (NF2), also widely known as Merlin, is a member of the ezrin-radixin-moesin (ERM) protein family that functions as a critical tumor suppressor by linking the actin cytoskeleton to the plasma membrane [3, 6, 9, 20]. It plays an essential role in mediating contact-dependent inhibition of cell proliferation and regulating fundamental cellular processes such as cell-cell adhesion, motility, and apoptosis [3, 7, 9, 23]. Merlin exerts its suppressive effects by modulating several key signaling pathways, most notably the Hippo, mTOR, and Ras/MAPK cascades, which are frequently hyperactivated upon its loss [1, 5, 14, 21]. Clinically, mutations or deletions in the NF2 gene lead to Neurofibromatosis type 2, a genetic syndrome characterized by the development of multiple benign tumors of the nervous system, including bilateral vestibular schwannomas, meningiomas, and ependymomas [1, 2, 6, 11, 21]. Therapeutic interventions for NF2-related conditions primarily focus on inhibiting these downstream pathways or targeting tumor-associated angiogenesis, as direct pharmacological restoration of the lost protein remains a significant challenge [1, 4, 15].

Other names

MerlinSchwannominNeurofibromin-2Moesin-ezrin-radixin-like proteinBilateral acoustic neurofibromatosis protein

Because NF2 is a tumor suppressor that is typically lost or inactivated in disease, therapeutic strategies focus on inhibiting the downstream signaling pathways that become hyperactivated in its absence, such as mTOR (inhibited by Everolimus), MEK/ERK (inhibited by Selumetinib), and EGFR/ErbB2 (inhibited by Lapatinib), or reducing tumor-associated angiogenesis and edema through VEGF inhibition (Bevacizumab) [1, 5, 8, 14, 15].